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ASCO 2010 – Neuro-Oncology is moving! 
 
The 2010 ASCO meeting was one of the most exciting ASCO meetings for Neuro-
Oncology ever, with first presentations of various large phase III trials as well as first 
reports on several novel treatment approaches. 
 
Combined temozolomide-based radiochemotherapy using temozolomide is 
considered standard of care for glioblastoma patients aged 65-70. Radiotherapy 
alone is usually considered standard of care in the elderly. The results of two large 
phase III trials challenging this standard were presented. The Nordic Brain Tumor 
Trial compared conventional radiotherapy (30 x 2 Gy) with hypofractionated 
radiotherapy (10 x 3.4 Gy) and a conventional regimen of temozolomide (5 out of 28 
days) in 342 patients with glioblastoma > 60 years of age. The median survival times 
in the three arms were 6, 7.5 and 8 months, and these differences were not 
significant (#LBA2002). The German NOA-08 trial (Methvsalem) randomized 412 
patients > 65 years of age with glioblastoma or anaplastic astrocytoma to 
conventional radiotherapy or dose-dense temozolomide chemotherapy (one week on 
one week off). The one year survival rate was 38% with radiotherapy compared with 
30% with chemotherapy, and this difference was significant. Moreover, radiotherapy 
was overall better tolerated (#LBA2001). These discrepant results are difficult to 
interprete until full publications become available, but a prudent conclusion would be 
to state that radiotherapy using either fractionation schedule remains the standard of 
care at present. Whether combined chemoradiation is superior to radiotherapy alone, 
is addressed in an ongoing phase III trial of NCIC and EORTC. 
 
The UK BR12 trial had randomized 447 chemonaive patients with recurrent 
malignant glioma to PCV polychemotherapy or temozolomide, with a 
subrandomization of the temozolomide patients to the conventional 5 out of 28 days 
regimen or a dose-dense 21 out of 28 days regimen. At the ASCO meeting, the 
investigators provided molecular analyses of this study: IDH1 mutations and MGMT 
promoter methylation were independent prognostic markers, independent of the 
applied treatment regimen (#2035). 
 
Updated results for one of the registration trials for bevacizumab in recurrent 
glioblastoma, the BRAIN study, were also presented. BRAIN had randomized the 
patients to treatment with either bevacizumab alone (n=85) or bevacizumab plus 
irinotecan (n=82). No new safety signals were reported, median survival times in both 
arms remained at 9.3 and 8.9 months, and survival at 30 months was 11% and 16%, 
respectively. Altogether, one major conclusion remains: the addition of irinotecan 
increased toxicity, but did not demonstrate activity over that seen with bevacizumab 
alone (#2008). The results from the dose-finding study for the integrin antagonist, 
cilengitide, were also reported. That study had randomized patients with recurrent 
glioblastoma to flat doses of 500 mg (n=41) or 2000 mg (n=40). At a median follow-
up of 53.3 and 48.3 months, respectively, survival rates were consistently higher with 
2000 mg at 12, 24, 36, 48 and 54 months. Again, no new safety signals were 
reported (#2010). Both agents, bevacizumab and cilengitide, are now explored in the 
first-line setting and aim at concluding patient enrolment prior to ASCO 2011. 
 
Perhaps most controversial were the lessons to be learnt from the German G-
PCNSL-SG-1 trial which randomized 551 patients with primary CNS lymphoma to 
high-dose methotrexate (HDMTX) followed either by whole brain radiotherapy 
(WBRT) alone or observation (for patients with complete remission (CR) after 
HDMTX) or WBRT or HD-Ara-C (for patients failing to achieve a CR after HDMTX). 
This study was criticized for several shortcomings, including high drop-out rate and 
high number of protocol violations. Nevertheless, the analysis of 318 patients treated 
per protocol demonstrated trends for longer progression-free survival, but shorter 
overall survival in patients treated with WBRT first-line. Neither of these differences 
were significant. Thus, the possible gain in event-free survival afforded by WBRT has 
to be weighed against the cognitive sequelae which appear to be inescapable in 
long-term survivors (#8008). 
 
Roger Stupp, Lausanne, Switzerland 
Michael Weller, Zurich, Switzerland 
 
